Seven Chinese-made COVID-19 vaccines enter phase-3 clinical trials: official
Share - WeChat


BEIJING - A total of seven Chinese-made COVID-19 vaccines have entered phase-3 clinical trials, according to an official with the Ministry of Science and Technology (MOST).
China now has 16 self-developed COVID-19 vaccines undergoing clinical trials, said Wu Yuanbin, director-general of science and technology for social development with MOST, at a recent conference on hematology.
An inactivated vaccine developed by Beijing Biological Products Institute Co Ltd under the China National Biotec Group (CNBG), affiliated with Sinopharm, was last month the first to receive conditional market approval from the National Medical Products Administration.
The interim results of its phase-3 clinical trials show 79.34 percent efficacy against COVID-19.
Related Stories
- 5 dead after entering abandoned mine in East China
- Andersson seizes victory in Shanghai F1H2O showdown
- Red alert as Typhoon Matmo makes landfall in South China
- New reception hall aims to transform Guangzhou into international trade hub
- Typhoon Matmo to make landfall on Sunday
- Mid-Autumn Festival event promotes cross-Strait harmony in Fuzhou